CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
52.96
+1.24 (2.40%)
At close: Sep 14, 2026, 4:00 PM EDT
52.55
-0.41 (-0.77%)
Pre-market: Sep 15, 2026, 6:26 AM EDT
CRISPR Therapeutics AG Revenue
CRISPR Therapeutics AG had revenue of $10.18M in the quarter ending June 30, 2026, with 1,041.37% growth. This brings the company's revenue in the last twelve months to $13.39M, down -64.80% year-over-year. In the year 2025, CRISPR Therapeutics AG had annual revenue of $3.51M, down -90.59%.
Revenue (ttm)
$13.39M
Revenue Growth
-64.80%
P/S Ratio
382.38
Revenue / Employee
$34,076
Employees
393
Market Cap
5.12B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.51M | -33.80M | -90.59% |
| Dec 31, 2024 | 37.31M | -333.89M | -89.95% |
| Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
| Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
| Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
| Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
| Dec 31, 2019 | 289.59M | 286.47M | 9,169.85% |
| Dec 31, 2018 | 3.12M | -37.87M | -92.38% |
| Dec 31, 2017 | 41.00M | 35.83M | 693.90% |
| Dec 31, 2016 | 5.16M | 4.92M | 1,990.69% |
| Dec 31, 2015 | 247.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.14B |
| PTC Therapeutics | 1.01B |
| Ligand Pharmaceuticals | 290.54M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
| Dianthus Therapeutics | 1.90M |
CRSP News
- 17 hours ago - CRISPR Therapeutics AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 days ago - CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 17 days ago - CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 - GlobeNewsWire
- 17 days ago - CRISPR Therapeutics AG Slides: Corporate presentation - Filings
- 6 weeks ago - CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 6 weeks ago - CRISPR Therapeutics AG Earnings release: Q2 2026 - Filings
- 6 weeks ago - CRISPR Therapeutics AG Quarterly report: Q2 2026 - Filings
- 2 months ago - CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices - FXEmpire